Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 61

1.

Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome.

Koelzer VH, Dawson H, Andersson E, Karamitopoulou E, Masucci G, Lugli A, Zlobec I.

Transl Res. 2015 Mar 4. pii: S1931-5244(15)00083-3. doi: 10.1016/j.trsl.2015.02.008. [Epub ahead of print]

PMID:
25797890
3.

Tumour border configuration in colorectal cancer: proposal for an alternative scoring system based on the percentage of infiltrating margin.

Karamitopoulou E, Zlobec I, Koelzer VH, Langer R, Dawson H, Lugli A.

Histopathology. 2015 Feb 4. doi: 10.1111/his.12665. [Epub ahead of print]

PMID:
25648412
4.

TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer.

Galván JA, Helbling M, Koelzer VH, Tschan MP, Berger MD, Hädrich M, Schnüriger B, Karamitopoulou E, Dawson H, Inderbitzin D, Lugli A, Zlobec I.

Oncotarget. 2015 Jan 20;6(2):874-85.

5.

Tyrosine kinase receptor B (TrkB) expression in colorectal cancers highlights anoikis resistance as a survival mechanism of tumour budding cells.

Dawson H, Grundmann S, Koelzer VH, Galván JA, Kirsch R, Karamitopoulou E, Lugli A, Inderbitzin D, Zlobec I.

Histopathology. 2015 Apr;66(5):715-25. doi: 10.1111/his.12603. Epub 2014 Dec 23.

PMID:
25382057
6.

Glucagon-like-peptide-1 receptor expression in normal and diseased human thyroid and pancreas.

Waser B, Blank A, Karamitopoulou E, Perren A, Reubi JC.

Mod Pathol. 2015 Mar;28(3):391-402. doi: 10.1038/modpathol.2014.113. Epub 2014 Sep 12.

PMID:
25216224
7.

Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches.

Karamitopoulou E, Thies S, Zlobec I, Ott K, Feith M, Slotta-Huspenina J, Lordick F, Becker K, Langer R.

Am J Surg Pathol. 2014 Nov;38(11):1551-6. doi: 10.1097/PAS.0000000000000255.

PMID:
25140894
8.

Investigation of IL-23 (p19, p40) and IL-23R identifies nuclear expression of IL-23 p19 as a favorable prognostic factor in colorectal cancer: a retrospective multicenter study of 675 patients.

Helbling M, Lukesch A, Haimovici A, Karamitopoulou E, Berger MD, Hädrich M, Mallaev M, Schnüriger B, Koelzer VH, Dawson H, Borner M, Langer R, Rosenberg R, Nitsche U, Inderbitzin D, Lugli A, Tschan M, Zlobec I.

Oncotarget. 2014 Jul 15;5(13):4671-82.

9.

Increased number of non-degranulated mast cells in pancreatic ductal adenocarcinoma but not in acute pancreatitis.

Karamitopoulou E, Shoni M, Theoharides TC.

Int J Immunopathol Pharmacol. 2014 Apr-Jun;27(2):213-20.

PMID:
25004833
10.

HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker.

Sconocchia G, Eppenberger-Castori S, Zlobec I, Karamitopoulou E, Arriga R, Coppola A, Caratelli S, Spagnoli GC, Lauro D, Lugli A, Han J, Iezzi G, Ferrone C, Ferlosio A, Tornillo L, Droeser R, Rossi P, Attanasio A, Ferrone S, Terracciano L.

Neoplasia. 2014 Jan;16(1):31-42.

11.

Loss of Raf-1 kinase inhibitor protein (RKIP) is strongly associated with high-grade tumor budding and correlates with an aggressive phenotype in pancreatic ductal adenocarcinoma (PDAC).

Karamitopoulou E, Zlobec I, Gloor B, Kondi-Pafiti A, Lugli A, Perren A.

J Transl Med. 2013 Dec 14;11:311. doi: 10.1186/1479-5876-11-311.

12.

Pretreatment with sevoflurane attenuates direct lung injury.

Kalimeris K, Zerva A, Matsota P, Nomikos T, Fragopoulou E, Politi AN, Karamitopoulou E, Kostopanagiotou G.

Minerva Anestesiol. 2014 Jun;80(6):635-44. Epub 2013 Dec 4.

PMID:
24299917
13.

Neonatal Fc receptor expression in dendritic cells mediates protective immunity against colorectal cancer.

Baker K, Rath T, Flak MB, Arthur JC, Chen Z, Glickman JN, Zlobec I, Karamitopoulou E, Stachler MD, Odze RD, Lencer WI, Jobin C, Blumberg RS.

Immunity. 2013 Dec 12;39(6):1095-107. doi: 10.1016/j.immuni.2013.11.003. Epub 2013 Nov 27.

14.

Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.

Dawson H, Galván JA, Helbling M, Muller DE, Karamitopoulou E, Koelzer VH, Economou M, Hammer C, Lugli A, Zlobec I.

Int J Cancer. 2014 May 15;134(10):2342-51. doi: 10.1002/ijc.28564. Epub 2013 Nov 13.

PMID:
24166180
15.

The apoptotic and proliferation rate of tumour budding cells in colorectal cancer outlines a heterogeneous population of cells with various impacts on clinical outcome.

Dawson H, Koelzer VH, Karamitopoulou E, Economou M, Hammer C, Muller DE, Lugli A, Zlobec I.

Histopathology. 2014 Mar;64(4):577-84. doi: 10.1111/his.12294. Epub 2013 Dec 28.

PMID:
24111856
16.

Role of epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma: is tumor budding the missing link?

Karamitopoulou E.

Front Oncol. 2013 Sep 17;3:221. doi: 10.3389/fonc.2013.00221. Review.

17.

The growing galectin network in colon cancer and clinical relevance of cytoplasmic galectin-3 reactivity.

Dawson H, André S, Karamitopoulou E, Zlobec I, Gabius HJ.

Anticancer Res. 2013 Aug;33(8):3053-9.

PMID:
23898060
18.

Tumour budding is a strong and independent prognostic factor in pancreatic cancer. Reply to comment.

Karamitopoulou E, Gloor B.

Eur J Cancer. 2013 Jul;49(10):2458-9. doi: 10.1016/j.ejca.2013.03.028. Epub 2013 May 7. No abstract available.

PMID:
23664012
19.

Geographic analysis of RKIP expression and its clinical relevance in colorectal cancer.

Koelzer VH, Karamitopoulou E, Dawson H, Kondi-Pafiti A, Zlobec I, Lugli A.

Br J Cancer. 2013 May 28;108(10):2088-96. doi: 10.1038/bjc.2013.197. Epub 2013 Apr 30.

20.

Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer.

Karamitopoulou E.

Front Oncol. 2013 Jan 4;2:209. doi: 10.3389/fonc.2012.00209. eCollection 2012.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk